Gynecologic malignant neoplasms manifest later among individuals with PMS2 variants, with an incidence of more than 1% before age 50 years.3,4 Our findings suggest that current guidelines recommending prophylactic surgical treatment at age 40 years potentially increase risk of negative outcomes associated with premature menopause with minimal value. This evidence concerns the gene PMS2 and female reproductive organ cancer.